- Business Wire•5 days ago
Ironwood Pharmaceuticals, Inc. today announced the closing of a $150 million debt refinancing. Ironwood will use the net proceeds from this transaction to redeem the remaining principal balance of its existing Linaclotide PhaRMA 11% Notes due 2024.
- Benzinga•9 days ago
BTIG believes Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) provides more than 15 percent upside from the current levels, pointing out the pipeline opportunities. In the current month alone, the stock ...
- Capital Cube•17 days ago
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Ironwood Pharmaceuticals, Inc. a score of 44. Our analysis is based on comparing Ironwood Pharmaceuticals, Inc. with the following peers – Progenics Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Nektar Therapeutics, Astrazeneca PLC Sponsored ADR, Sucampo Pharmaceuticals, Inc. Class A, Cumberland Pharmaceuticals Inc. and Synthetic Biologics, Inc. (PGNX-US, SGYP-US, ... Read more (Read more...)
Ironwood Pharmaceuticals, Inc. (IRWD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||12.75 x 500|
|Day's Range||15.17 - 15.93|
|52wk Range||7.35 - 16.17|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-23.60|
|Avg Vol (3m)||1,163,046|
|Dividend & Yield||N/A (N/A)|